What is the reported incidence of reflux on semaglutide in SUSTAIN-6?

The specifics, since they change the answer: reflux · semaglutide · SUSTAIN-6.

I have the document in front of me and I can read the numbers. What I cannot do is interpret them.

I am reasonably comfortable with statistics and completely uncomfortable with chromatography, or vice versa.

What does this actually establish, and what does it not?

Take it from the SUSTAIN-6 adverse-event table by arm, and check the unit before you use it. An incidence can be the proportion of participants who reported the event at least once, or the count of events divided by exposure time, and the two differ by however many people had it repeatedly. Then subtract the placebo arm, because the untreated rate is not zero. And read the discontinuation column beside it: an event that made people leave the trial is under-counted at every later visit, so a low late-timepoint incidence can mean the event was severe rather than rare.

The short version: dose-related, escalation-concentrated, mostly attenuating except for constipation, and manageable by titration pace more than anything else.

The practical hierarchy of interventions: slow the titration, reduce meal size, reduce fat, separate fluids from meals, and only then consider symptomatic treatment.

Local reaction versus infection

Symptom prevalence in trials, broadly: nausea a quarter to a half, diarrhoea and constipation each roughly ten to twenty per cent, vomiting rather less, with all rates rising with dose.

The caveat is that severe persistent symptoms, particularly with dehydration or severe pain, are clinical and not a matter of waiting them out.

New symptoms at a stable dose after months need a different explanation.

The honest answer is that the first eight weeks are the hard part and that most people who get through them stop having the conversation.

Reflux occurs because a slower-emptying stomach retains volume for longer against a lower oesophageal sphincter that has not changed. Smaller meals and not lying down within a few hours are the direct responses.

Discontinuation for gastrointestinal effects in the trials runs in the low single-figure percentages, which means the great majority of people who experience these effects continue.

Nothing here is medical advice.

Most people who report these effects continue. The discontinuation rate is low.

edited 17 Dec 2024 by Dr_Ilse_Vandenberg — added a caveat about sampling

Answer first: the gastrointestinal effects in this class share one mechanism — slowed gastric emptying plus central signalling — and present as nausea, fullness, reflux, constipation or diarrhoea depending on the person.

Anticipating a slower-than-label titration from the start is a legitimate approach and costs only time, since the exposure ceiling is the same.

In practice, symptoms that appear for the first time at a stable dose after months are not the ordinary pattern and warrant looking for another explanation.

Gastric emptying studies in this class quantify the delay directly and document its attenuation with continued exposure to the long-acting agents.

Slow the titration first. It is the intervention with the best evidence and the lowest cost.

edited 19 Nov 2024 by Dr_Tomas_Kral — added the placebo-arm figures

Start with which symptom predominates, because the management diverges sharply even though the mechanism does not.

Gastric emptying of a solid meal can be delayed substantially at initiation. The effect is largest early and attenuates over weeks for the long-acting agents, which is the mechanistic basis for the titration schedule.

Symptoms appearing late at a stable dose deserve a differential diagnosis rather than an assumption.

Smaller meals, less fat, fluids between rather than with. In that order.

The relevant physiology is that gastric emptying slows substantially and then partially normalises with continued exposure at a stable dose.

Fat is the macronutrient that slows emptying most on its own, so a high-fat meal on top of pharmacologically delayed emptying is the combination that produces the worst episodes.

Research-use compounds are not approved for human use.

Everything except constipation attenuates. Plan differently for that one.